US Patent

US9173881 — Therapeutic compositions containing macitentan

Method of Use · Assigned to Actelion Pharmaceuticals Ltd · Expires 2029-08-12 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a product containing macitentan, either alone or in combination with a prostacyclin receptor agonist.

USPTO Abstract

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Uptravi (SELEXIPAG) · AstraZeneca

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi
`U-1798`	—	Uptravi

Patent Metadata

Patent number: US9173881
Jurisdiction: US
Classification: Method of Use
Expires: 2029-08-12
Drug substance claim: No
Drug product claim: No
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.